Literature DB >> 32169983

Rare case of post-varicella membranoproliferative glomerulonephritis presenting with massive proteinuria.

Avirup Majumdar1, Virendra Atam2, Mayank Mishra2.   

Abstract

Chicken pox caused by varicella zoster virus is usually a self-limiting disease causing rare life-threatening complications. Involvement of the kidneys is infrequent during the course of the illness. Literature shows rare reports of acute glomerulonephritis following varicella infection. We report a case of 16-year-old boy presenting with anasarca with characteristic healed rashes of chicken pox. His urinalysis revealed a 'massive' nephrotic range proteinuria (16 g/24 hours), gross hematuria and pyuria. A percutaneous renal biopsy showed membranoproliferative glomerulonephritis. Most cases of post-varicella glomerulonephritis have been described in children, massive proteinuria of this range in an immunocompetent adolescent, being an extremely rare entity. Acute proliferative glomerulonephritis in such cases is usually an immune complex hypocomplementaemic glomerulonephritis in response to the zoster infection. Proteinuria in most patients is benign and self-limiting with few fatal reports of crescentic glomerulonephritis progressing to acute renal failure. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute renal failure; infections; nephrotic syndrome; proteinurea

Mesh:

Substances:

Year:  2020        PMID: 32169983      PMCID: PMC7069260          DOI: 10.1136/bcr-2019-233084

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Varicella glomerulonephritis preceding the cutaneous lesions.

Authors:  H Matsukura; M Murakami; H Sakaki; T Mitani; S Shimura
Journal:  Clin Nephrol       Date:  2009-08       Impact factor: 0.975

2.  Rapidly progressive glomerulonephritis associated with varicella infection.

Authors:  P C Singhal; K S Chug; M A Muthusethupathi
Journal:  J Pediatr       Date:  1977-10       Impact factor: 4.406

3.  Renal damage in chicken-pox.

Authors: 
Journal:  Br Med J       Date:  1968-08-03

4.  Tubulointerstitial nephritis with uveitis syndrome following varicella zoster reactivation.

Authors:  D Ljutić; M Glavina
Journal:  Nephron       Date:  1995       Impact factor: 2.847

5.  Steroids and varicella.

Authors:  N A Reiches; J F Jones
Journal:  Pediatrics       Date:  1993-08       Impact factor: 7.124

6.  Varicella: clinical manifestations, epidemiology and health impact in children.

Authors:  S R Preblud; W A Orenstein; K J Bart
Journal:  Pediatr Infect Dis       Date:  1984 Nov-Dec

7.  Severe varicella associated with steroid use.

Authors:  S F Dowell; J S Bresee
Journal:  Pediatrics       Date:  1993-08       Impact factor: 7.124

8.  Central nervous system manifestations of chickenpox.

Authors:  R Johnson; P E Milbourn
Journal:  Can Med Assoc J       Date:  1970-04-25       Impact factor: 8.262

9.  Acute glomerulonephritis following varicella infection.

Authors:  S A Zaki; P Shanbag; S Bhongade
Journal:  Indian J Nephrol       Date:  2012-01

10.  Varicella glomerulonephritis mimicking microscopic polyangiitis.

Authors:  Rashna Dass; Surjit Singh; Vijay Kumar; Kim Vaiphei; Sunil Agrawal; T Saeed; Ranjana W Minz
Journal:  Rheumatol Int       Date:  2004-01-23       Impact factor: 3.580

View more
  2 in total

1.  Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.

Authors:  Erin M Paradis; Oleg Tikhonov; Xin Cao; Susanna M Kharit; Aleksandr Fokin; Heather L Platt; Frederick Wittke; Veronika Jotterand
Journal:  Hum Vaccin Immunother       Date:  2021-10-26       Impact factor: 3.452

Review 2.  Virus-Associated Nephropathies: A Narrative Review.

Authors:  Christophe Masset; Paul Le Turnier; Céline Bressollette-Bodin; Karine Renaudin; François Raffi; Jacques Dantal
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.